Brief: Sino Biopharmaceutical Says Positive Results From Phase III Study Of Benmelstobart Injection
27/12/2024 01:27
Dec 27 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK :
* BENMELSTOBART INJECTION PRIMARY STUDY ENDPOINT
PROGRESSION-FREE
SURVIVAL MET
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up